Regorafenib 40mg Tablets

Regorafenib 40mg Tablets is a highly advanced, oral multi-kinase inhibitor designed to systematically block the biological pathways that drive tumor growth and progression. As a potent pharmaceutical agent, Regorafenib 40mg Tablets functions through a “triple-action” mechanism: it inhibits the formation of new blood vessels (angiogenesis), targets the cellular structures that support the tumor microenvironment (stromal maintenance), and directly blocks the signals that tell cancer cells to replicate (oncogenic proliferation). By effectively deactivating specific receptor tyrosine kinases—including VEGFR-1, -2, -3, TIE2, KIT, RET, RAF-1, and BRAF—Regorafenib 40mg Tablets cuts off the tumor’s nutrient supply while simultaneously halting its internal growth machinery. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for patients with advanced gastrointestinal and liver malignancies, offering effective relief and a proven survival benefit in cases where previous standard therapies have ceased to be effective.

The unique pharmacological profile of Regorafenib 40mg Tablets is specifically engineered for “salvage therapy” or later-line treatment, providing a new avenue of hope for patients with refractory disease. Unlike highly specific single-target drugs, the broad-spectrum activity of Regorafenib 40mg Tablets prevents the tumor from activating alternative survival pathways, a common mechanism of drug resistance. The 40mg tablet strength is critical for the drug’s dosing flexibility, allowing oncologists to carefully titrate the medication to manage toxicity while maintaining therapeutic efficacy.

Indications / Uses of Regorafenib 40mg Tablets

Regorafenib 40mg Tablets is commonly prescribed for the specialized management of the following aggressive oncological conditions:

• Metastatic Colorectal Cancer (mCRC): It is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as well as anti-VEGF therapy and, if RAS wild-type, anti-EGFR therapy. Regorafenib 40mg Tablets provides effective relief by stabilizing the disease when other options have been exhausted.
• Gastrointestinal Stromal Tumors (GIST): The medication is used for patients with locally advanced, unresectable, or metastatic GIST who have been previously treated with imatinib mesylate and sunitinib malate. In these cases, Regorafenib 40mg Tablets offers a powerful alternative to control tumor growth.
• Hepatocellular Carcinoma (HCC): It is prescribed for patients with hepatocellular carcinoma (liver cancer) who have been previously treated with sorafenib. Regorafenib 40mg Tablets serves as a second-line standard of care to extend overall survival in liver cancer patients.
• Angiogenesis Suppression: By targeting the vascular endothelial growth factor (VEGF) pathway, the drug is used generally to suppress the complex network of blood vessels that feed solid tumors.

Key Features

• Broad-Spectrum Kinase Inhibition: The primary feature of Regorafenib 40mg Tablets is its ability to inhibit over a dozen different enzymes, creating a comprehensive blockade against cancer cell survival.
• Oral Tablet Formulation: The medication offers the convenience of home-based administration. The standard dose typically involves taking four 40mg tablets (160mg total) once daily, allowing for easy adjustment (e.g., reducing to three or two tablets) if side effects occur.
• Targeted Microenvironment Control: Unlike cytotoxic chemotherapy that kills all dividing cells, Regorafenib 40mg Tablets modifies the tumor’s surroundings, making it hostile for cancer cells to grow or metastasize.
• Proven Survival Extension: Clinical trials have consistently demonstrated that Regorafenib 40mg Tablets significantly increases overall survival and progression-free survival in patients with mCRC, GIST, and HCC.
• Dosing Cycle Structure: The therapy is typically administered in 28-day cycles (21 days on treatment, followed by 7 days off), a schedule designed to allow the body to recover from the drug’s powerful effects.

Storage for Regorafenib 40mg Tablets

To preserve the chemical stability and ultimate potency of the active ingredients, Regorafenib 40mg Tablets must be stored in their original bottle at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). It is vital to keep the bottle tightly closed and to leave the desiccant (drying agent) inside the bottle to protect the tablets from moisture. Moisture can rapidly degrade the tablet matrix and reduce clinical effectiveness. Once the bottle is opened, the medication is typically good for only 7 weeks (49 days); any remaining tablets after this period should be discarded. For maximum safety, always store Regorafenib 40mg Tablets in a secure, dry location that is strictly out of the reach and sight of children and pets. Do not transfer the tablets to a daily pill box, as they require the protection of the original container.

Important Note on Regorafenib 40mg Tablets

The administration of Regorafenib 40mg Tablets requires strict adherence to dietary instructions. The tablets should be taken with a low-fat breakfast (containing less than 30% fat). Taking the medication with a high-fat meal can alter its absorption, while taking it on an empty stomach may reduce its effectiveness. Patients should swallow the tablets whole with water at the same time each day.

A Boxed Warning exists for severe hepatotoxicity (liver injury). Healthcare providers must monitor liver function tests (ALT, AST, bilirubin) prior to initiation and at least every two weeks during the first two months of treatment. Regorafenib 40mg Tablets is also associated with Hand-Foot Skin Reaction (HFSR), a condition causing redness, swelling, blistering, and pain on the palms and soles. Preventive skin care, including the use of moisturizers and wearing comfortable shoes, is recommended. Other serious risks include hypertension (high blood pressure), cardiac ischemia, and gastrointestinal perforation. Fatigue, diarrhea, and voice changes (dysphonia) are common side effects. Because the drug can cause fetal harm, effective contraception must be used by both men and women during treatment and for 2 months after the final dose. By strictly following these professional guidelines and attending regular safety monitoring, patients can maximize the powerful benefits of Regorafenib 40mg Tablets.